Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Nanocationite [25Mg]PMC16: Experimental research of topical use in adrenalin induced glaucoma

17th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems
October 04-06, 2018 Moscow, Russia

Alyabyeva Zhanna Yurievna, Egorov E A, Romanova T B, Dxzukaeva D S, Suhorukov V S and Baranich T I

Pirogov Russian National Research Medical University, Russia

Scientific Tracks Abstracts: Int J Drug Dev & Res

Abstract:

Mitochondrial oriented medicines are perspective for the glaucomatous optic neuropathy treatment. Fullerenebased low toxic nanocationite particles (PMC16) with 25Mg2+ belong to the abovementioned group. Nanoparticles of a magnetic isotope of magnesium (25Mg-PMC16) are characterized by low toxicity and membranotropic antioxidant effect. Positive antiapoptotic and antioxidant effects of Mg, fullerene, and porphyrin that exist within structure of this nanoparticle have been previously known. The aim of the work was to determine the opportunity of the intraocular use of 25Mg-PMC16 in healthy rabbits (10 μg, 100 μg and 1000 μg) and in case of adrenalin induced glaucoma (10 μg) as well as intraocular pressure (IOP) dynamics and eye tissue reaction for the intracameral and intravitreal injection of 25Mg-PMC16 .The eyes were characterized in vivo by means of biomicroscopy and direct ophthalmoscopy, post mortem - by light microscopy, IOP was measured by Maklakov tonometer. Results: there were no inflammation or toxic reaction by in vivo control and histologic examination in all doses of the nanocationite. Temporal mild IOP increase was found in the case of 10 μg of PMC16 with Mg252+ use in the group of rabbits without ocular hypertension, and IOP decreased in rabbits with ocular hypertension. Conclusion: the dose 10 μg of nanocationit PMC16 with Mg25 2+ is safe (induce no inflammation or toxic reactions) for the intracameral and intravitreal use and does not opacificate optic media, decreasing intraocular pressure in the eyes with elevated IOP and moderately increasing it in the eyes with low IOP during the period of 14 days after the injection.

Biography :

Alyabyeva Zhanna Yurievna has completed her PhD in Ophthalmology as well as postdoctoral studies at Pirogov Russian National Research Medical University. She worked as a professor of ophthalmology in National Medico- Surgical Center by N.I. Pirogov and practicing ophthalmologist in Moscow Glaucoma Center, now she is a leading researcher in the Scientific Research Group of Glaucoma and Dystrophic Eye Disease (Pirogov Russian National Research Medical University) and laser surgeon in Laser Ophthalmology Department (Moscow City Hospital #15 named by O.M. Filatov). She has published more than 50 papers in reputed journals.

E-mail: ann-mari@yandex.ru